Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2011-000426-29
    Sponsor's Protocol Code Number:I1Q-MC-JDDE
    National Competent Authority:Spain - AEMPS
    Clinical Trial Type:EEA CTA
    Trial Status:Completed
    Date on which this record was first entered in the EudraCT database:2012-08-20
    Trial results View results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedSpain - AEMPS
    A.2EudraCT number2011-000426-29
    A.3Full title of the trial
    A Phase 2 Randomized Study to Investigate the Efficacy and Safety of LY2495655 Versus Placebo in Older Patients Undergoing Elective Total Hip Arthroplasty (eTHA)
    Estudio aleatorizado de fase 2 en el que se compara la eficacia y seguridad de LY2495655 y placebo en pacientes mayores que tengan programado someterse a una artroplastia total de cadera (eTHA)
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    A Study in Older Patients Undergoing Elective Total Hip Replacement
    Estudio en pacientes mayores que tengan programado someterse a una artroplastia total de cadera
    A.4.1Sponsor's protocol code numberI1Q-MC-JDDE
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorLilly S.A.
    B.1.3.4CountrySpain
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportEli Lilly and Company
    B.4.2CountryUnited States
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationEli Lilly
    B.5.2Functional name of contact pointClinical Trial Information
    B.5.3 Address:
    B.5.3.1Street AddressAvda de la industria 30
    B.5.3.2Town/ cityAlcobendas Madrid
    B.5.3.3Post code28108
    B.5.3.4CountrySpain
    B.5.4Telephone number34916635354
    B.5.5Fax number34916633481
    B.5.6E-mailEU_Lilly_Clinical_Trials@lilly.com
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameLY2495655 for Injection
    D.3.2Product code LY2495655
    D.3.4Pharmaceutical form Lyophilisate for solution for injection
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPSubcutaneous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNN/A
    D.3.9.1CAS number N/A
    D.3.9.2Current sponsor codeLY2495655
    D.3.9.3Other descriptive nameLY2495655
    D.3.9.4EV Substance CodeN/A
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number53
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin No
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) Yes
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product Yes
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    D.8 Placebo: 1
    D.8.1Is a Placebo used in this Trial?Yes
    D.8.3Pharmaceutical form of the placeboSolution for injection
    D.8.4Route of administration of the placeboSubcutaneous use
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Disuse atrophy
    Artrofia por desuso
    E.1.1.1Medical condition in easily understood language
    Muscle wasting which includes shrinking of the muscle and weakness. This can occur when a muscle is no longer as active as usual.
    Desgaste muscular lo que incluye contracción de los músculos y debilidad. Esto puede suceder cuando un músculo ya no está tan activo como siempre.
    E.1.1.2Therapeutic area Diseases [C] - Musculoskeletal Diseases [C05]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 14.1
    E.1.2Level LLT
    E.1.2Classification code 10013521
    E.1.2Term Disuse muscle atrophy
    E.1.2System Organ Class 10028395 - Musculoskeletal and connective tissue disorders
    E.1.3Condition being studied is a rare disease No
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    The primary objective of this study is to test the hypothesis that appendicular lean body mass (aLBM) will increase after 12 weeks of LY2495655 treatment versus placebo in older patients undergoing elective total hip arthroplasty (eTHA).
    El objetivo principal de este estudio es evaluar la hipótesis de que la masa corporal magra de las extremidades (MCMe) se incrementará tras 12 semanas de tratamiento con LY2495655 (comparado con placebo), en pacientes mayores que se sometan a una artroplastia total de cadera
    programada (eTHA).
    E.2.2Secondary objectives of the trial
    To evaluate the safety and tolerability of LY2495655 versus placebo, as assessed by treatment emergent adverse events (TEAEs), serious adverse events (SAEs), vital signs, and safety laboratory tests.

    To evaluate the effect of LY2495655 versus placebo on leg extension strength as assessed with a leg press.
    Explorar los cambios en la MCMe, la masa grasa y la densidad mineral ósea de la totalidad del cuerpo.? Comparar el efecto de LY2495655 vs placebo, en relación a:
    o Fuerza de extensión de la pierna.
    o Prueba cronometrada de "levantarse y caminar?
    o Tiempo y fuerza empleados en la prueba de subir escaleras.
    o Fuerza de prensión de la mano.
    o Utilización de ayudas para caminar.
    o Escala de Funcionalidad de las Extremidades Inferiores?
    o Nº de días de hospitalización, incluidas las cirugías y la rehabilitación
    o Nº de sesiones de rehabilitación desde la última visita.
    o Caídas y lesiones.
    o Dolor de la cadera, (Escala de Valoración Numérica).
    ? Farmacocinética LY2495655.
    ? Relación entre la concentración plasmat de LY2495655 y criterios de eficacia,
    ? Efecto de distintas covariables sobre la eficacia de LY2495655,
    Variantes genéticas o los genes implicados de la ruta de la miostatina (asociados con variabilidad en la eficacia o seguridad LY2495655.)
    E.2.3Trial contains a sub-study Yes
    E.2.3.1Full title, date and version of each sub-study and their related objectives
    Protocol Addendum I1Q-MC-JDDE(2) approved 22Feb2011
    A Phase 2 Randomized Study to Investigate the Efficacy and Safety of LY2495655 Versus Placebo in Older Patients Undergoing Elective Total Hip Arthroplasty (eTHA) ? Six Minute Walk Addendum.
    Adenda al protocolo I1Q-MC-JDDE(2)
    Estudio aleatorizado de fase I1Q-MC-JDDE en el que se compara la eficacia y seguridad de 2 y placebo en pacientes mayores que tengan programado someterse a una artroplastia total de cadera (eTHA)
    E.3Principal inclusion criteria
    Males or females age 60 years or older.

    Elective total hip arthroplasty (eTHA) is scheduled.

    Have a body mass index of <40 kg/ m² and a weight <136.4 kg.

    Can climb at least 6 stairs with or without holding the handrail (but without human assistance), according to the patient at the screening visit.

    Can stand up from a chair and walk more than 10 meters without human assistance

    Take at least 12 seconds to perform the Timed Up and Go (TUG) test at the screening visit.
    [1] Varones o mujeres que no estén en edad de procrear, de ? 50 años de edad.
    [1a] Los varones cuya pareja femenina esté en edad fértil deberán utilizar un método anticonceptivo durante el período de tratamiento del estudio y las 15 semanas posteriores a la última dosis del fármaco en fase de investigación.
    [1b] Se considerará que las mujeres no están en edad de procrear si:
    · Tienen ? 60 años de edad y su última menstruación se ha producido al menos 12 meses antes de la inclusión en el estudio.
    · O tienen < 60 años de edad y su última menstruación se ha producido al menos 12 meses antes de la inclusión en el estudio y presentan una concentración sérica de hormona estimulante del folículo (FSH) de
    ? 40 UI/L y una concentración sérica de estradiol de ? 20 pg/ml o ? 73 pmol/l,
    · O se han sometido a una ovariectomía bilateral y/o a una histerectomía y/o ligación de trompas (y esto está claramente documentado).
    [2] Tener previsto someterse a una eTHA entre 4-16 días después de la visita 2
    (visita de aleatorización). Esta cirugía puede ser bien una eTHA primaria, debido a la presencia de artrosis en la cadera, o una cirugía de revisión tras el fracaso de la THA primaria que se realizara para tratar la artrosis de cadera.
    [3] Presentar un índice de masa corporal (IMC) < 40 kg/ m² y un peso <136,4 kg.
    [4] Poder subir, en la visita 1, al menos 6 escalones (ayudándose o no del pasamanos ?sin ayuda de terceros?), de acuerdo con la opinión del paciente.
    [5] Poder levantarse de una silla y caminar más de 10 metros sin la asistencia de
    terceras personas (se permite utilizar bastón/es, muletas o andador).
    [6] Necesitar al menos 12 segundos para realizar la Prueba Cronometrada de
    ?levantarse y caminar? (TUG) en la visita 1.
    [7] Que los resultados de los análisis clínicos realizados durante la selección se
    encuentren en el intervalo de referencia para dicha población, o los resultados
    presenten desviaciones aceptables que el investigador no considere clínicamente significativas.
    [8] Presentar un acceso venoso suficiente para permitir la extracción de muestras
    sanguíneas, de acuerdo con el protocolo.
    [9] Estar disponible durante la duración del estudio, capaz de desplazarse para
    realizar las visitas del estudio y dispuesto a seguir los procedimientos del mismo.
    [10] Haber proporcionado su consentimiento informado por escrito, que debe ser aprobado por Lilly y por el correspondiente Comité Ético del centro (CEIC).
    E.4Principal exclusion criteria
    1. Another inpatient surgical procedure is planned in the 6 months following the randomization visit.
    2. Lower extremity amputation.
    3. Lower limb fracture within 6 months prior to the screening visit.
    4. Simultaneous bilateral eTHA.
    5. The planned surgical procedure will preclude weight bearing for at least 4 weeks postoperatively (for instance, the planned procedure will involve extensive bone grafting). ?Partial weight bearing? and ?weight bearing as tolerated? are acceptable, but ?non weight-bearing,? ?touch weight bearing,? or ?feather weight bearing? are exclusive.
    6. Underlying muscle disease (for example, polymyositis or muscular dystrophy) or a history of muscle disease other than age-associated muscle waste or disuse atrophy.
    7. Recent neurologic injury (<6 months prior to randomization) such as stroke or spinal cord injury, or unstable neurologic disorders that are likely to confound physical performance tests during the course of the study (such as unstable Parkinson disease or hemiplegia).
    8. History of positive testing for human immunodeficiency virus (HIV).
    9. Current us or previous us of any substances known to influence muscle mass or performance within 6 months prior to randomization (this includes anabolic steroids, replacement therapy for gonadal deficiency, growth hormone, IGF1, or any other agent used to build muscle mass), or systemic corticosteroid use for at least 3 months prior to randomization at a daily dose ?10 mg prednisone equivalent.
    10. Severe Vitamin D deficiency defined as 25-hydroxy-vitamin D levels <9.2 ng/mL or <23 pmol/mL at the screening visit.
    11. History of a malignant neoplasm in the 5 years prior to the screening visit, with the exception of superficial basal cell carcinoma or squamous cell carcinoma of the skin that has been definitively treated. Patients with carcinoma in situ of the uterine cervix treated definitively more than 1 year prior to screening may enter the study.
    12. History of any of the following conditions within 90 days of the screening visit: Unstable angina, myocardial infarction, coronary artery bypass graft surgery, or percutaneous coronary intervention (eg, angioplasty or stent placement).
    13. Any current supraventricular arrhythmia with an uncontrolled ventricular response (mean heart rate >100 beats per minute) at rest despite medical or device therapy, or any history of spontaneous or induced sustained ventricular tachycardia (heart rate >100 bpm for 30 seconds) despite medical or device therapy, or any history of resuscitated cardiac arrest or the presence of an automatic internal cardioverter-defibrillator.
    14. Any history of congestive heart failure within 6 months of the screening visit.
    15. Systolic blood pressure >160 or <90 mm Hg or diastolic blood pressure >100 or <50 mm Hg at screening visit (if stress is suspected, retest under basal conditions), or malignant hypertension.
    16. An abnormality in the locally read 12-lead electrocardiogram (ECG) that in the opinion of the investigator increases the risk of participating in the study or a Bazett?s corrected QT interval >450 milleseconds for men and >470 milleseconds for women.
    17. Have either or both of the following: Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) >2 times the upper limit of normal (ULN), or alkaline phosphatase >1.5 times ULN, or total bilirubin >1.5 times ULN. The liver tests above may be repeated once within a week if the initial response exceeds this limit, and the lesser value accepted if it meets this criterion; Known history or presence of severe acute or chronic liver disease.
    18. History of significant renal insufficiency, defined as receiving renal dialysis or having an estimated creatinine clearance ?30 mL/minute at the screening visit.
    19. Evidence or recent history of significant psychiatric disease such as dementia/Alzheimer?s disease, schizophrenia, or bipolar disorder.
    20. Are currently enrolled in, or discontinued within the last 30 days (or 5 half lives whichever is longer) from a clinical trial involving an investigational drug or off-label use of a drug, or are concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study.
    21. Regularly uses known drugs of abuse and/or shows positive findings on urinary drug screening (physician prescribed narcotics are allowed).
    22. Have a positive fecal occult blood (FOB) test at screening or the patient cannot provide a stool sample for FOB testing within the visit window prior to randomization.
    [11] Procedimiento quirúrgico que requiera la hospitalización del paciente, en el transcurso de los 6 meses posteriores a la visita 2.
    [12] Una amputación de una extremidad inferior.
    [13] Fractura en una extremidad inferior durante los 6 meses previos a la visita 1, o cualquier cirugía mayor de las extremidades inferiores en los 3 meses previos a la visita 2.
    [14] eTHA bilateral simultánea.
    [15] Procedimiento quirúrgico programado impida descarga de peso al menos durante las 4 semanas posteriores a la intervención
    [16] Presencia de enfermedad muscular subyacente o antecedentes de enfermedad muscular
    [17] Lesiones neurológicas recientes (< 6 meses antes de la aleatorización).
    [18] VIH positivo.
    [19] Consumo en los 6 meses previos a la aleatorización de fármacos que influyan en la masa o el desempeño muscular, o corticoesteroides sistémicos al menos durante 3 meses (en el último año) antes de la aleatorización, a una dosis diaria equivalente de prednisona ? 10 mg.
    [20] Insuficiencia grave de vitamina D,(< 9,2 ng/ml o < 23 nmol/l, en la visita de selección.)
    [21] Antecedentes de neoplasia maligna en los 5 años previos a la visita 1,.
    [22] Antecedentes de cualquiera de las siguientes enfermedades en el transcurso de los 90 días previos a la visita 1: [22a] Angina inestable, según se define en el anexo 4 (Braunwald, 1989).
    [22b] Infarto de miocardio.
    [22c] Revascularización coronaria.
    [22d] Intervención coronaria percutánea
    [23] Presentar en la actualidad cualquier arritmia con respuesta ventricular incontrolada (frecuencia cardiaca promedio >100 ppm) ?en reposo, a pesar de recibir tratamiento médico o con algún tipo de dispositivo?, o antecedentes de taquicardia ventricular espontánea o taquicardia ventricular inducida sostenida (frecuencia cardiaca >100 ppm durante 30 segundos) ?a pesar de recibir tratamiento médico o con algún tipo de dispositivo?, o antecedentes de paro cardiaco (paciente reanimado) o utilización de un desfibrilador automático interno.
    [24] Antecedentes de insuficiencia cardiaca congestiva (Clase ? II de la New York Heart Association [NYHA], anexo 5) en el transcurso de los 6 meses previos a la visita 1.
    [25] Tensión arterial sistólica >160 o < 90 mm Hg o tensión arterial diastólica >100 o < 50 mm Hg en la visita 2, o hipertensión maligna.
    [26] Presencia de una alteración en el electrocardiograma (ECG) de 12 derivaciones realizado localmente que, en opinión del investigador, suponga un riesgo adicional si el paciente participa en el estudio.
    [27] Presentar uno de los siguientes criterios o ambos:
    [27a] Aspartato aminotransferasa (AST) o alanina aminotransferasa (ALT) > 2 veces el límite superior de la normalidad (LSN), o fosfatasa alcalina > 1,5 veces el LSN o bilirrubina total > 1,5 veces el LSN.
    [27b] Antecedentes conocidos o presencia de enfermedad hepática aguda o crónica.
    [28] Antecedentes de insuficiencia renal significativa, esto es, estar recibiendo diálisis renal o presentar en la visita 1 un aclaramiento de creatinina estimado < 30 ml/minuto, de acuerdo con una estimación realizada por el laboratorio central, basándose en la fórmula de Cockroft-Gault: [(140-edad) x (peso en kg) x (0,85 [mujeres])] / (A x creatinina sérica), donde A = 0,814 si la concentración de creatinina sérica se expresa en umol/l, o A = 72 la concentración de creatinina sérica se expresa en mg/dl.
    [29] Antecedentes recientes o indicios de presentar en la actualidad una enfermedad psiquiátrica significativa, entre otras, demencia/enfermedad de Alzheimer, esquizofrenia o trastorno bipolar.
    [30] Ser personal del centro de investigación, directamente relacionado con el estudio, y/o familiares cercanos
    [31] Ser empleado de Lilly de la organización externa (TPO) que se haya designado para asistir en la realización del estudio.
    [32] Estar participando en la actualidad o haber abandonado en el transcurso de los últimos 30 días (o 5 semividas, lo que sea mayor) un ensayo clínico.
    [33] Uso regular de drogas conocidas y/o resultados positivos en una prueba de detección de tóxicos en orina (se permite que el paciente tome narcóticos prescritos por un médico).
    [34] Antecedentes recientes de consumo excesivo de alcohol
    [35] Presentar alergias conocidas a LY2495655, sus constituyentes o los compuestos relacionados.
    [36] Haber completado o haber sido retirado de este o de cualquier otro estudio en el que se investigue LY2495655 o cualquier otro fármaco en fase de investigación cuyo efecto específico sea la inhibición de la miostatina.
    [37] Presentar resultados positivos en una prueba de detección de sangre oculta en las heces.
    [38] Presentar diabetes mellitus no controlada.
    [39] Haber sufrido un traumatismo ocular o haberse sometido a cirugía oftalmológica o a un tratamiento con láser ocular, en el transcurso de los 6 meses previos a la aleatorización.
    E.5 End points
    E.5.1Primary end point(s)
    Change from baseline in appendicular lean body mass.
    cambio desde el inicio del estudio en la masa corporal magra
    E.5.1.1Timepoint(s) of evaluation of this end point
    12 weeks after the first injection
    12 semanas despues de la primera inyeccion
    E.5.2Secondary end point(s)
    Leg extension strength
    Safety
    Fuerza de la extension de la pierna
    Seguridad
    E.5.2.1Timepoint(s) of evaluation of this end point
    Weeks 4, 8,12,16,24 (after first injection)
    semana 4, 8, 12, 16, 24 despues de la primera inyeccion
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy Yes
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic Yes
    E.6.7Pharmacodynamic Yes
    E.6.8Bioequivalence No
    E.6.9Dose response Yes
    E.6.10Pharmacogenetic Yes
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others No
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) Yes
    E.7.3Therapeutic confirmatory (Phase III) No
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled Yes
    E.8.1.1Randomised Yes
    E.8.1.2Open No
    E.8.1.3Single blind No
    E.8.1.4Double blind Yes
    E.8.1.5Parallel group Yes
    E.8.1.6Cross over No
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) No
    E.8.2.2Placebo Yes
    E.8.2.3Other No
    E.8.2.4Number of treatment arms in the trial4
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned4
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA12
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA Yes
    E.8.6.2Trial being conducted completely outside of the EEA No
    E.8.6.3If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned
    Canada
    Denmark
    Estonia
    Finland
    United States
    E.8.7Trial has a data monitoring committee No
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    LVLS
    Ultima visita del ultimo paciente
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years1
    E.8.9.1In the Member State concerned months6
    E.8.9.1In the Member State concerned days0
    E.8.9.2In all countries concerned by the trial years1
    E.8.9.2In all countries concerned by the trial months6
    E.8.9.2In all countries concerned by the trial days0
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1Number of subjects for this age range: 0
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) No
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 50
    F.1.3Elderly (>=65 years) Yes
    F.1.3.1Number of subjects for this age range: 290
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations No
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception No
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state50
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 120
    F.4.2.2In the whole clinical trial 340
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    Normal standard of care.
    Tratamiento habitual para su enfermedad
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2012-11-06
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2012-10-10
    P. End of Trial
    P.End of Trial StatusCompleted
    P.Date of the global end of the trial2014-02-19
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 04 21:53:03 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA